NCT06706921View on ClinicalTrials.gov

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate CancerMale Urogenital DiseasesProstatic DiseasesUrogenital Diseases, MaleGenital Diseases, MaleNeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, Male
Interventions
DRUG

18F-Fluciclovine PET/CT Scan

In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.

Trial Locations (1)

90073

RECRUITING

VA Greater Los Angeles Healthcare System, Los Angeles

All Listed Sponsors
lead

VA Greater Los Angeles Healthcare System

FED